Methods and compositions for Mycoplasma pneumoniae exotoxins

Details Methods and compositions for Mycoplasma pneumoniae exotoxins Methods and compositions for Mycoplasma pneumoniae exotoxins

2004-10-01

2009-11-24

Devi, S. (Department: 1645)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C424S264100, C424S184100, C424S234100

Reexamination Certificate

active

07622571

ABSTRACT:
The present invention provides aMycoplasma pneumoniaecommunity acquired respiratory distress syndrome (CARDS) toxin, biologically active fragments/domains of the CARDS toxin, antibodies to the CARDS toxin and nucleic acids encoding the CARDS toxin. Also provided are methods of diagnosing, treating and/or preventing infection byMycoplasma pneumoniaeusing the compositions provided herein.

REFERENCES:
patent: 5534413 (1996-07-01), Lo et al.
patent: 6100380 (2000-08-01), Green et al.
patent: 2003/0176331 (2003-09-01), Rosenblum et al.
patent: 2004/0191260 (2004-09-01), Reiter et al.
patent: 2006/0057155 (2006-03-01), Masignani et al.
patent: WO 02/079242 (2002-10-01), None
Dandekar et al. “Re-annotating theMycoplasma pneumoniaegenome sequence: adding value, function and reading frames”Nucleic Acids Research28(17) 3278-3288 (2000).
Himmelreich et al. “Complete sequence analysis of the genome of the bacteriumMycoplasma pneumoniae”Nucleic Acids Research24(22) 4420-4449 (1996).
Hott et al. “Skeletal muscle-specific immunotoxin for the treatment of focal muscle spasm”Neurology50(2):485-491 (1998).
International Search Report and Written Opinion for PCT/US05/11897; Date of mailing Aug. 28, 2006.
International Search Report and Written Opinion for PCT/US04/33037; Date of mailing Oct. 11, 2005.
Kannan et al. “Identification and Characterization of Human Surfactant Protein A Binding Protein ofMycoplasma pneumoniae” Infection and Immunity73(5):2828-2834.
Kannan et al. “ADP-ribosylating and vacuolating cytotoxin ofMycoplasma pneumoniaerepresents unique virulence determinant among bacterial pathogens”PNAS103(17):6724-6729 (2006).
Pallen et al. “An abundance of bacterial ADP-ribosyltransferases—implications for the origin of oxotoxins and their human homologues”Trends in Microbiology9(7):302-307 (2001).
Barile et al. “Experimentally induced septic arthritis in chimpanzees infected withMycoplasma hominis, Mycoplasma pneumoniae, andUreaplasma urealyticum” Clin Infect Dis. 18(5):694-703 (1994) (Abstract Only).
International Search Report for PCT/US05/12266; mailed Oct. 10, 2006.
Himmelreich et al. Accession No. P753409, Hypothetical protein MPN372 (Feb. 1, 1997).
Masignani et al. Accession No. AAE29374,Mycoplasma pneumoniaADP-ribosylating toxin protein (Jan. 27, 2003).
Sasaki et al. “The complete genomic sequence ofMycoplasma penetrans, an intracellular bacterial pathogen in humans”Nucleic Acids Research30(23):5293-5300 (2002).

Affiliated with

Also associated with

Rating

Methods and compositions for Mycoplasma pneumoniae exotoxins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods and compositions for Mycoplasma pneumoniae exotoxins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for Mycoplasma pneumoniae exotoxins will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4130719